{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:40:22Z","timestamp":1730799622214,"version":"3.28.0"},"reference-count":30,"publisher":"Akademiai Kiado Zrt.","issue":"40","license":[{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2024,10,6]]},"abstract":"<jats:p>Az acromegali\u00e1s betegek v\u00e1rhat\u00f3 t\u00fal\u00e9l\u00e9se, \u00e9letmin\u0151s\u00e9ge rosszabb, mint az\n                    eg\u00e9szs\u00e9ges popul\u00e1ci\u00f3\u00e9. Ennek h\u00e1tter\u00e9ben a diagn\u00f3zis k\u00e9s\u00e9se \u00e9s a m\u0171t\u00e9t ut\u00e1n is\n                    sokszor megmarad\u00f3 acromegalia-aktivit\u00e1s \u00e1ll. \u00cdgy eset\u00fckben k\u00fcl\u00f6n\u00f6sen fontos a\n                    gyors, hat\u00e9kony \u00e9s egy\u00e9nre szabott endokrinol\u00f3giai kezel\u00e9s \u00e9s gondoz\u00e1s. 1965-\u00f6s\n                    sz\u00fclet\u00e9s\u0171 n\u0151beteg\u00fcnket 2008 \u00f3ta gondozt\u00e1k tenzi\u00f3s jelleg\u0171 fejf\u00e1j\u00e1s miatt.\n                    2012-ben sella-MR-vizsg\u00e1lat 13 mm-es hypophysis-macroadenom\u00e1t igazolt, melynek\n                    teljes, transsphenoidalis m\u0171t\u00e9ti elt\u00e1vol\u00edt\u00e1sa megt\u00f6rt\u00e9nt. A sz\u00f6vettani vizsg\u00e1lat\n                    somatrotrop adenom\u00e1t mutatott. Posztoperat\u00edv or\u00e1lis gl\u00fck\u00f3ztolerancia-teszt sor\u00e1n\n                    biok\u00e9miailag akt\u00edv acromegali\u00e1t \u00e9szlelt\u00fcnk negat\u00edv sella-MR-k\u00e9p mellett, \u00edgy\n                    dopaminagonista kezel\u00e9s indult, majd az inzulinszer\u0171 n\u00f6veked\u00e9si faktor-1\n                    emelked\u0151 szintje \u00e9s fokoz\u00f3d\u00f3 fejf\u00e1j\u00e1s miatt els\u0151 gener\u00e1ci\u00f3s\n                    szomatosztatinreceptorligand (SRL)-kezel\u00e9sre t\u00e9rt\u00fcnk \u00e1t. \u00daj kelet\u0171 cukorbetegs\u00e9g\n                    miatt a beteg biguanid-, majd izulinter\u00e1pi\u00e1t ig\u00e9nyelt. Progredi\u00e1l\u00f3 panaszok\n                    miatt n\u00f6veked\u00e9sihormonreceptor-antagonista kezel\u00e9sre v\u00e1ltottunk, mely r\u00e9szleges\n                    betegs\u00e9gkontrollt eredm\u00e9nyezett, \u00e9s nem v\u00e1ltoztak a p\u00e1ciens \u00e9letmin\u0151s\u00e9g\u00e9t\n                    jelent\u0151sen ront\u00f3 fejf\u00e1j\u00e1sos panaszok sem. Ez\u00e9rt egy \u00e9vtizednyi ter\u00e1pi\u00e1s\n                    pr\u00f3b\u00e1lkoz\u00e1s ut\u00e1n a fenn\u00e1ll\u00f3 diabetes mellitus ellen\u00e9re m\u00e1sodik gener\u00e1ci\u00f3s\n                    SRL-kezel\u00e9s mellett d\u00f6nt\u00f6tt\u00fcnk, mely a fejf\u00e1j\u00e1st azonnal megsz\u00fcntette, \u00e9s az\n                    addig akt\u00edv acromegali\u00e1t kontroll\u00e1lta. A szomatosztatin-receptor (SSTR)\n                    alt\u00edpus\u00e1nak ut\u00f3lagos vizsg\u00e1lata domin\u00e1ns SSTR5-expresszi\u00f3t igazolt. Diabetes\n                    mellitusszal sz\u00f6v\u0151d\u00f6tt acromegalia eset\u00e9n is lehet optim\u00e1lis ter\u00e1pia a\n                    pazireotid, amennyiben a daganat SSTR5-expresszi\u00f3t mutat. Orv Hetil. 2024;\n                    165(40): 1587\u20131593.<\/jats:p>","DOI":"10.1556\/650.2024.33156","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T04:01:29Z","timestamp":1728273689000},"page":"1587-1593","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Az acromegalia kezel\u00e9s\u00e9nek neh\u00e9zs\u00e9gei 12 \u00e9v pr\u00f3b\u00e1lkoz\u00e1s t\u00fckr\u00e9ben"],"prefix":"10.1556","volume":"165","author":[{"given":"Erna","family":"Guly\u00e1s","sequence":"first","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, I. Belgy\u00f3gy\u00e1szati Klinika, Endokrinol\u00f3gia \u00e9s Anyagcsere Oszt\u00e1ly P\u00e9cs, Ifj\u00fas\u00e1g u. 13., 7624 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kriszti\u00e1n","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Orvosi K\u00e9palkot\u00f3 Klinika P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9la","family":"Kajt\u00e1r","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Pathol\u00f3giai Int\u00e9zet P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Radics","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Pathol\u00f3giai Int\u00e9zet P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"D\u00f3czi","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Idegseb\u00e9szeti Klinika P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emese","family":"Mez\u0151si","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, I. Belgy\u00f3gy\u00e1szati Klinika, Endokrinol\u00f3gia \u00e9s Anyagcsere Oszt\u00e1ly P\u00e9cs, Ifj\u00fas\u00e1g u. 13., 7624 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Nemes","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, I. Belgy\u00f3gy\u00e1szati Klinika, Endokrinol\u00f3gia \u00e9s Anyagcsere Oszt\u00e1ly P\u00e9cs, Ifj\u00fas\u00e1g u. 13., 7624 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1 Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015; 17(Suppl 4): 1-62.","DOI":"10.1093\/neuonc\/nov189"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3171\/2010.8.JNS10290","article-title":"Atypical pituitary adenomas: incidence, clinical characteristics, and implications","volume":"114","author":"2 Zada","year":"2011","unstructured":"2 Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg. 2011; 114: 336-344.","journal-title":"J Neurosurg"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3 T\u00f3th M. Aggressive pituitary adenoma and pituitary carcinoma. [Agressz\u00edv hypophysisadenoma \u00e9s hypophysiscarcinoma.] Orv Hetil. 2023; 164: 1167-1175. [Hungarian]","DOI":"10.1556\/650.2023.32832"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrendo.2014.64","article-title":"Diagnosis and emerging treatments","volume":"10","author":"Ieva A","year":"2014","unstructured":"4 Di Ieva A, Rotondo F, Syro LV, et al. Aggressive pituitary adenomas. Diagnosis and emerging treatments. Nat Rev Endocrinol. 2014; 10: 423-435.","journal-title":"Nat Rev Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/cancers12020514","article-title":"How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020","volume":"12","author":"5 Trouillas","year":"2020","unstructured":"5 Trouillas J, Jaffrain-Rea ML, Vasiljevic A, et al. How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel) 2020; 12: 514-531.","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"6 Holdaway","year":"2008","unstructured":"6 Holdaway IM, Bolland MJ, Gamble GD, et al. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008; 159: 89-95.","journal-title":"Eur J Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"7 Giustina","year":"2020","unstructured":"7 Giustina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020; 21: 667-678.","journal-title":"Rev Endocr Metab Disord"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8 Hargittay Cs, D\u00e9nes J, Hubina E, et al. The role of the general practitioner in the care of acromegalic patients, with glucose metabolism dysfunction in the focus. [A h\u00e1ziorvos szerepe az acromegali\u00e1s betegek gondoz\u00e1s\u00e1ban, f\u00f3kuszban a sz\u00e9nhidr\u00e1t-anyagcsere zavara.] Orv Hetil. 2020; 161: 1724-1729. [Hungarian]","DOI":"10.1556\/650.2020.31777"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"9 Melmed","year":"2018","unstructured":"9 Melmed S, Bronstein MD, Chanson C, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018; 14: 552-561.","journal-title":"Nat Rev Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1530\/eje.1.01863","article-title":"The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'","volume":"152","author":"10 Nomikos","year":"2005","unstructured":"10 Nomikos P, Buchfelder M, Fahlbusch R, et al. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol. 2005; 152: 379-387.","journal-title":"Eur J Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12020-017-1458-3","article-title":"Microsurgical therapy of pituitary adenomas","volume":"59","author":"11 Mortini","year":"2018","unstructured":"11 Mortini P, Barzaghi LR, Albano L, et al. Microsurgical therapy of pituitary adenomas. Endocrine 2018; 59: 72-81.","journal-title":"Endocrine"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.nec.2019.05.009","article-title":"Endocrine outcomes after pituitary surgery","volume":"30","author":"Buttan A","year":"2019","unstructured":"12 Buttan A, Mamelak AN. Endocrine outcomes after pituitary surgery. Neurosurg Clin N Am. 2019; 30: 491-498.","journal-title":"Neurosurg Clin N Am"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s11102-017-0832-8","article-title":"Surgical debulking of pituitary adenomas improves responsiveness to octreotide LAR in the treatment of acromegaly","volume":"20","author":"13 Fahlbusch","year":"2017","unstructured":"13 Fahlbusch R, Kleinberg D, Biller B, et al. Surgical debulking of pituitary adenomas improves responsiveness to octreotide LAR in the treatment of acromegaly. Pituitary 2017; 20: 668-675.","journal-title":"Pituitary"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"14 Hofland","year":"2004","unstructured":"14 Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004; 89: 1577-1585.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","article-title":"Effects of lanreotide SR and autogel on tumor mass in patients with acromegaly: a systematic review","volume":"13","author":"Mazziotti G","year":"2010","unstructured":"15 Mazziotti G, Giustina A. Effects of lanreotide SR and autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010; 13: 60-67.","journal-title":"Pituitary"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"16 Bruns","year":"2002","unstructured":"16 Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002; 146: 707-716.","journal-title":"Eur J Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study","volume":"182","author":"17 Colao","year":"2020","unstructured":"17 Colao A, Bronstein MD, Brue T, et al. Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study. Eur J Endocrinol. 2020; 182: 583-594.","journal-title":"Eur J Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","article-title":"Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly","volume":"53","author":"18 Schmid","year":"2016","unstructured":"18 Schmid HA, Brue T, Colao A, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 2016; 53: 210-219.","journal-title":"Endocrine"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1507\/endocrj.51.227","article-title":"Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide","volume":"51","author":"19 Park","year":"2004","unstructured":"19 Park C, Yang I, Woo J, et al. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J. 2004; 51: 227-236.","journal-title":"Endocr J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s12022-007-9004-0","article-title":"Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide","volume":"18","author":"20 Takei","year":"2007","unstructured":"20 Takei M, Suzuki M, Kajiya H, et al. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocr Pathol. 2007; 18: 208-216.","journal-title":"Endocr Pathol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"21 Bhayana","year":"2005","unstructured":"21 Bhayana S, Booth GL, Asa SL, et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab. 2005; 90: 6290-6295.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1210\/jc.2008-0126","article-title":"Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas","volume":"93","author":"22 Fusco","year":"2008","unstructured":"22 Fusco A, Zatelli MC, Bianchi A, et al. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab. 2008; 93: 2746-2750.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000322787","article-title":"Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53","volume":"94","author":"23 Kasuki Jomori de Pinho","year":"2011","unstructured":"23 Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, et al. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 2011; 94: 39-48.","journal-title":"Neuroendocrinology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1677\/ERC-09-0094","article-title":"Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications","volume":"16","author":"24 Jaffrain-Rea","year":"2009","unstructured":"24 Jaffrain-Rea ML, Angelini M, Gargano D, et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer 2009; 16: 1029-1043.","journal-title":"Endocr Relat Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/humu.21292","article-title":"Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families","volume":"31","author":"25 Igreja","year":"2010","unstructured":"25 Igreja S, Chahal HS, King P, et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat. 2010; 31: 950-960.","journal-title":"Hum Mutat"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"26 Ferone","year":"2008","unstructured":"26 Ferone D, de Herder WW, Pivonello R, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008; 93: 1412-1417.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"27 Iacovazzo","year":"2016","unstructured":"27 Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016; 174: 241-250.","journal-title":"Eur J Endocrinol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11102-016-0753-y","article-title":"Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly","volume":"20","author":"Tritos NA","year":"2017","unstructured":"28 Tritos NA, Biller BM. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Pituitary 2017; 20: 129-135.","journal-title":"Pituitary"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"29 Fleseriu","year":"2021","unstructured":"29 Fleseriu M, Biller BM, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary 2021; 24: 1-13.","journal-title":"Pituitary"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30 Kaniuka-Jakubowska S, Levy MJ, Pal A, et al. A study of acromegaly-associated headache with somatostatin analgesia. Endocr Relat Cancer 2023; 30: e220138.","DOI":"10.1530\/ERC-22-0138"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/165\/40\/article-p1587.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/165\/40\/article-p1587.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/165\/40\/article-p1587.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:02:29Z","timestamp":1730797349000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/165\/40\/article-p1587.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,6]]},"references-count":30,"journal-issue":{"issue":"40"},"URL":"https:\/\/doi.org\/10.1556\/650.2024.33156","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"type":"print","value":"0030-6002"},{"type":"electronic","value":"1788-6120"}],"subject":[],"published":{"date-parts":[[2024,10,6]]}}}